Supernus Pharmaceuticals reported $177.35M in Sales Revenues for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbott ABT:US USD 10.09B 319M
Ani Pharmaceuticals ANIP:US USD 83.82M 9.97M
Aurora Cannabis Inc ACB:CN CAD 49.26M 952K
Bristol Myers Squibb BMY:US USD 11.22B 669M
Canopy Growth Corp WEED:CN CAD 117.86M 7.75M
Cara Therapeutics CARA:US USD 10.81M 12.19M
Corcept Therapeutics CORT:US USD 101.73M 1.66M
Eisai 4523:JP JPY 174.36B 9.9B
Eli Lilly And LLY:US USD 6.94B 453.6M
Endo International Ordinary Shares ENDP:US USD 541.69M 27.42M
Horizon Pharma HZNP:US USD 925.36M 48.95M
Lannett LCI:US USD 75.08M 890K
Marinus Pharmaceuticals MRNS:US USD 2.34M 550K
Pacira Pharmaceuticals PCRX:US USD 167.47M 1.94M
Perrigo Ordinary Shares PRGO:US USD 1.1B 21.5M
Pfizer PFE:US USD 22.64B 5.1B
Revance Therapeutics RVNC:US USD 29.01M 647K
Supernus Pharmaceuticals SUPN:US USD 177.35M 7.3M
Teva Pharmaceutical Industries TEVA:US USD 3.6B 191M
United Therapeutics UTHR:US USD 516M 49.1M
Xeris Pharmaceuticals Inc XERS:US USD 29.72M 4.42M